Effective treatment of ovarian cancer using triciribine and related compounds
US9433635B2 · kind B2 · utility
0Cited by
0References
7Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Nov 6, 2014 |
| Grant date | Sep 6, 2016 |
| Priority date | — |
| Expiry date | Nov 6, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/57449
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat ovarian cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.